
Avantor’s Mary Blenn outlines five considerations for biopharma supply chain localization, from customer demand visibility to cost, consistency and redundancy.
Click the title above for a link to open the Pharmaceutical Commerce April 2023 issue in an interactive PDF format.
over 3 years ago
Keeping Up with the Actionover 3 years ago
Assessing Drug Pricing in Europeover 3 years ago
Pediatric Medicine: Challenges Aboundover 3 years ago
Ramping Up DSCSA Readiness Effortsover 3 years ago
High-Tech Hubs and Specialty Pharmaover 3 years ago
What is a Digital Hub in 2023?over 3 years ago
Patient Hubs in an Omnichannel Worldover 3 years ago
Solving the Omnichannel Puzzle





